ArticleJCO precision oncology2023
Trametinib in Patients With
Open access · hybridAbstract read
In one paragraph
Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 14 citations in OpenAlex.
- Precision therapeutic strategies for advanced gastrointestinal stromal tumors.Cancer metastasis reviews · 2026Review
- Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma.Molecular cancer · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Targeting Radiation-Induced Glioma-Initiating Cells in Patient-Derived Glioblastoma.bioRxiv : the preprint server for biology · 2025Article
- NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma.Cancer research · 2025Article
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboringFrontiers in oncology · 2025Article
- Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.International journal of molecular sciences · 2024Article
- MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.Molecular cancer therapeutics · 2024Article
- Basket Trials: Past, Present, and Future.Annual review of cancer biology · 2024Article
- Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.Vision (Basel, Switzerland) · 2024Review
- Pharmacogenomics and Big Data in medical oncology: developments and challenges.Therapeutic advances in medical oncology · 2024Review
- Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place.NPJ precision oncology · 2023Review
- The Cardiofaciocutaneous Syndrome: From Genetics to Prognostic-Therapeutic Implications.Genes · 2023Review
- Article
- The NCI-MATCH trial: lessons for precision oncology.Nature medicine · 2023Review
- Durable disease control in a radiation-induced high-grade glioma harboringNeuro-oncology advancesArticle
- Identifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 14 institutions in 1 country.
Kari B WisinskiDepartment of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI.ORCID 0000-0003-3535-0652
Yael FlamandDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0003-2150-6732
Melissa A WilsonDepartment of Oncology, Division of Hematology/Medical Oncology, St Luke's University Health Network, Easton, PA.ORCID 0000-0002-5391-7838
Jason J LukeDivision of Hematology/Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA.ORCID 0000-0002-1182-4908
Hussein A TawbiMD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1942-851X
Fangxin HongDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0001-8049-0086
Edith P MitchellThomas Jefferson University Hospital, Philadelphia, PA.
James A ZwiebelInvestigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-4455-8789
Helen ChenCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Robert J GrayDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0002-5724-4917
Shuli LiDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Lisa M McShaneBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-8195-3206
Lawrence V RubinsteinBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9720-9737
David PattonCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3855-0166
P Mickey WilliamsFrederick National Laboratory for Cancer Research, Frederick, MD.ORCID 0000-0002-3309-5988
Stanley R HamiltonDepartment of Pathology, City of Hope, Duarte, CA.ORCID 0000-0002-8331-1052
Robert J BehrensIowa-Wide Oncology Research Association NCORP, Des Moines, IA.ORCID 0000-0002-0223-4076
Kathryn P PenningtonFred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0003-0959-4370
Barbara A ConleyCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1445-1684
Carlos L ArteagaUniversity of Texas Southwestern Medical Center, Dallas, TX.
Lyndsay N HarrisCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9774-6719
Peter J O'DwyerUniversity of Pennsylvania, Philadelphia, PA.
Alice P ChenDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2919-4326
Keith T FlahertyMassachusetts General Hospital, Boston, MA.ORCID 0000-0002-3402-0478
National Cancer Institute · USDana-Farber Cancer Institute · USCity of Hope · USFrederick National Laboratory for Cancer Research · USFred Hutch Cancer Center · USIowa Oncology Research Association · USMassachusetts General Hospital · USSt. Luke's University Health Network · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · USThomas Jefferson University Hospital · USUniversity of Pennsylvania · USUniversity of Wisconsin Carbone Cancer Center · USUPMC Hillman Cancer Center · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MIowa-Wide Oncology Research Coalition (I-WORC)UG1CA189816 · NCI · IOWA ONCOLOGY RESEARCH ASSOCIATION · PI Seema Harichand, Arshin Sheybani · 2014 to 2026
$14.9MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MNCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer CenterUG1CA233184 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ADAM M BRUFSKY, John Munn Kirkwood · 2019 to 2026
$7.7MUT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4UG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI David Eric Gerber · 2019 to 2026
$6.4MNational Clinical Trials Network Research at the University of WisconsinUG1CA233277 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Lisa M Barroilhet, Andrew M. Baschnagel · 2019 to 2026
$4.9MHutchinson Center as Lead Academic Participating Site (UG1)UG1CA233328 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Yu · 2019 to 2026
$4.3MNCI NIH HHS P30 CA014520NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189816NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233184NCI NIH HHS UG1 CA233277NCI NIH HHS UG1 CA233302NCI NIH HHS UG1 CA233328NCI NIH HHS UG1 CA233329NCI NIH HHS UG1 CA233341
Abstract
purposeNCI-MATCH is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatment subprotocols. This report combines two subprotocols evaluating trametinib, a MEK1/2 inhibitor, in patients with
methodsEligible patients had tumors with deleterious inactivating
resultsFifty patients were eligible and started therapy: 46 with
conclusionAlthough these subprotocols did not meet the primary end point for ORR, significant responses or prolonged SD noted in some disease subtypes warrants further investigation.
Indexed as
MelanomaNeurofibromatosis 1GTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11HumansPyridonesPyrimidinonesGNA11 protein, humanGNAQ protein, humanGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11PyridonesPyrimidinonestrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.